AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Blue print medicine stock8/3/2023 ![]() Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. ![]() BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. See Notice NOT-OD-19-128Īugust 23, 2019- Clarifying Competing Application Instructions and Notice of Publication of Frequently Asked Questions (FAQs) Regarding Proposed Human Fetal Tissue Research. July 26, 2019- Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research. JNotice of Clarification to Application Types Allowed PAR-20-111. PAR-21-162- Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) See Notice NOT-OD-21-170ĪpExpanding Requirement for eRA Commons IDs to All Senior/Key Personnel. See Notice NOT-OD-21-169.ĪugUpdate: Notification of Upcoming Change in Federal-wide Unique Entity Identifier Requirements. See NoticeĪugNew NIH "FORMS-G" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2022. SeptemUpdates to the Non-Discrimination Legal Requirements for NIH Recipients. OctoReminder: FORMS-G Grant Application Forms & Instructions Must be Used for Due Dates On or After JanuNew Grant Application Instructions Now Available. Notice of Change Key Dates for PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)". NOT-OD-22-190 - Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022 ![]() NOT-OD-23-012 Reminder: FORMS-H Grant Application Forms and Instructions Must be Used for Due Dates On or After JanuNew Grant Application Instructions Now Available FebruNotice of Change to Minimum Performance Standards for SBIR and STTR Applicants.
0 Comments
Read More
Leave a Reply. |